NASDAQ:AMGN - Amgen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$191.12 -0.37 (-0.19 %)
(As of 03/21/2019 06:50 AM ET)
Previous Close$191.49
Today's Range$189.87 - $192.77
52-Week Range$163.31 - $210.19
Volume2.35 million shs
Average Volume3.00 million shs
Market Capitalization$118.93 billion
P/E Ratio13.27
Dividend Yield3.03%
Beta1.21
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$23.75 billion
Cash Flow$18.0472 per share
Book Value$19.62 per share

Profitability

Net Income$8.39 billion

Miscellaneous

Employees21,500
Market Cap$118.93 billion
Next Earnings Date4/23/2019 (Estimated)
OptionableOptionable

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen announced a quarterly dividend on Thursday, March 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $1.45 per share on Friday, June 7th. This represents a $5.80 annualized dividend and a dividend yield of 3.03%. The ex-dividend date is Thursday, May 16th. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen announced that its board has approved a stock buyback plan on Friday, February 2nd 2018, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) posted its quarterly earnings data on Tuesday, January, 29th. The medical research company reported $3.42 EPS for the quarter, topping the Zacks' consensus estimate of $3.26 by $0.16. The medical research company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $5.88 billion. Amgen had a net margin of 35.35% and a return on equity of 66.74%. During the same quarter in the prior year, the business posted $2.89 EPS. View Amgen's Earnings History.

When is Amgen's next earnings date?

Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, April 23rd 2019. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY19 earnings guidance on Tuesday, January, 29th. The company provided EPS guidance of $13.10-14.30 for the period, compared to the Thomson Reuters consensus estimate of $14.66. The company issued revenue guidance of $21.8-22.9 billion, compared to the consensus revenue estimate of $22.92 billion.Amgen also updated its FY 2019 guidance to $13.10-14.30 EPS.

What price target have analysts set for AMGN?

17 equities research analysts have issued 12-month price targets for Amgen's stock. Their predictions range from $179.00 to $234.00. On average, they expect Amgen's share price to reach $208.0588 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Price Targets for Amgen.

What is the consensus analysts' recommendation for Amgen?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. Mizuho analysts commented, "We also plan to unveil our buyside survey results in full detail and provide additional commentary on what we’re hearing from investors. This webinar will last 60 minutes. We will have slides (and I can’t promise a replay). Hope you can tune in. ===Ways to Access this Webinar=== 1. Link to add this webinar to your calendar ==> Click Here 2. Full-length URL (to use on day of webinar … click on it or cut/paste into your browser) ==> https://mizuhogroup.webex.com/mizuhogroup/onstage/ g.php?MTID=e55aa48dfcfbba81a9521ea1537d2ea77 3. Need audio-only cuz you’re travelling? ==> Email Me Please call / email with any questions – Salim PLEASE REFER TO PAGE 3 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports." (2/13/2019)
  • 2. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the approval of migraine candidate, Aimovig was a huge boost. Its strong biosimilars pipeline could be an important long-term growth driver. Amgen’s restructuring plan is making more cost efficient. Lower taxes and share buybacks should provide some bottom-line support. Amgen’s shares have outperformed the industry in the past year. However, Amgen faces challenges related to its more mature products such as launch of competing biosimilar versions of Neulasta and Epogen, further sales erosion of Neupogen and Aranesp and increasing competitive pressures on Enbrel. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. Nonetheless, estimates have gone down slightly ahead of the Q4 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (1/23/2019)
  • 3. Cantor Fitzgerald analysts commented, "We visited Amgen’s headquarters in conjunction with our post ASH bus tour and met the company’s CFO, R&D head, and IR team. We highlight key takeaways in this note. Management continues to sound very bullish about the Aimovig launch even as competitors launch. We could expect a decision on the Sandoz case around the mediation in Jan. We would expect 2019 guidance range to be as wide or a bit wider than 2018 due to biosimilars. From speaking to management, we think the biggest moving piece is Neulasta experiencing now two biosimilar competitors. When looking at analogs, the company notes drug lost about 50% share, but Amgen has the OnPro device, which may allow it to slow the rate of branded loss. Sensipar ($1.7B ’18 Bloomberg consensus) is a moving piece since generics have not launched at risk." (12/4/2018)

Has Amgen been receiving favorable news coverage?

Media headlines about AMGN stock have been trending very positive recently, according to InfoTrie. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amgen earned a media sentiment score of 3.4 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the stock's share price in the next several days.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Gilead Sciences (GILD), Johnson & Johnson (JNJ), Alibaba Group (BABA), Intel (INTC), Celgene (CELG), Pfizer (PFE), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO) and Walt Disney (DIS).

Who are Amgen's key executives?

Amgen's management team includes the folowing people:
  • Mr. Robert A. Bradway, Chairman & CEO (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Mr. Esteban Santos, Exec. VP of Operations (Age 51)
  • Mr. Mike Zahigian, Sr. VP & Chief Information Officer

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.24%), FMR LLC (5.32%), Oregon Public Employees Retirement Fund (4.93%), Northern Trust Corp (1.44%), Geode Capital Management LLC (1.42%) and Bank of New York Mellon Corp (1.07%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Polar Capital LLP, Pzena Investment Management LLC, Bank of New York Mellon Corp, Connor Clark & Lunn Investment Management Ltd., Assenagon Asset Management S.A., HM Payson & Co. and Rhumbline Advisers. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, Ronald D Sugar, Sean E Harper and Tyler Jacks. View Insider Buying and Selling for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, BlackRock Inc., Geode Capital Management LLC, Epoch Investment Partners Inc., Northern Trust Corp, Bahl & Gaynor Inc. and Two Sigma Advisers LP. View Insider Buying and Selling for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $191.12.

How big of a company is Amgen?

Amgen has a market capitalization of $118.93 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (NASDAQ AMGN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,256 (Vote Outperform)
Underperform Votes:  787 (Vote Underperform)
Total Votes:  2,043
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel